ArticleFrontiers in immunology2024

Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study.

Zhang Xuexian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.